Roger Bate ! Ideas for India

Roger Bate
American Enterprise Institute
Roger Bate is the author of Phake: The Deadly World of Falsified and Substandard Medicine. He is an Adjunct Scholar at the American Enterprise Institute (AEI), where he researches international health policy, with a special interest in medicine quality and malaria control. He has a Ph.D. in applied economics from Cambridge University. Dr Bate’s writings have appeared in, among others, the: New York Times, Washington Post, Wall Street Journal, Lancet, PLoS Medicine, Journal of Health Economics, Malaria Journal, and British Medical Journal. He regularly contributes to AEI's Health Policy Outlook series. He has been an advisor to the South African Government.

Dr Bate conducted extensive research in India and numerous Africa countries on the public health consequences of the counterfeit drug trade. He is the author or editor of 14 books and over 1,000 journal and newspaper articles.

His broader interests include aid policy in Africa and the developing world, evaluating the performance and effectiveness of WHO, USAID, the World Bank, NGOs, and other aid organisations and development policy initiatives. He writes extensively on topics such as endemic diseases in developing countries (malaria, HIV/AIDS); access to and innovation in pharmaceuticals; taxes and tariffs; water policy; and international health agreements.

He was the founder of the Frederic Bastiat Journalism Prize, and co-founder with Richard Tren of Africa Fighting Malaria, where he remains on the board of directors. He is also a fellow at the Institute of Economic Affairs in London and a visiting professor at the University of Buckingham in UK.

Articles By Roger Bate
Drug quality and global trade
Posted On: 18 Sep 2015

Topics:   Health , Trade
Tags:   Africa

There is a perception amongst pharmaceutical experts that some Indian manufacturers and/or their distributors segment the global medicine market into portions that are served by different quality medicines. This column finds that drug quality is poorer among Indian-labelled drugs purchased in African countries than among those purchased in India or middle-income countries. Substandard drugs – non-registered in Africa and containing insufficient amounts of the active ingredient – are the biggest driver of this quality difference.
read on »

Most Read

Twitter Feed